The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly’s Zepbound and Mounjaro.
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
The Danish drugmaker is working to convince European governments and insurers to reimburse the drug, seeking to position it as more than a lifestyle drug. Wegovy was launched in the U.S. in June 2021 but it took Novo until December 2022 to make all doses available there because of an initial production problem.
Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Both the FDA and EU regulators indicated visual acuity may serve as primary endpoint to evaluate MCO-010 in the treatment of low-vision retinitis pigmentosa patients.